-
Natera (NTRA) grew income 34.66% year-over-year in Q3 2025 and has rallied almost 70% since Q3 2025. Druckenmiller holds $517.4M in Natera.
-
Insmed (INSM) income surged 52.36% year-over-year in Q3 2025. The inventory climbed from $25 to $189 since Q2 2024.
-
Teva (TEVA) has rallied over 300% since June 2023. Druckenmiller amassed shares each quarter from Q3 2024 to Q3 2025.
-
When you’re excited about retiring or know somebody who’s, there are three fast questions inflicting many People to understand they’ll retire sooner than anticipated. take 5 minutes to study extra right here
Stanley Druckenmiller is a Wall Road legend whose trades are really value monitoring on account of how persistently he has been profitable. He has been piling into Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Prescribed drugs (NYSE:TEVA) as of late, and we’ll get into why.
Druckenmiller first gained fame by managing George Soros’s Quantum Fund, the place he orchestrated the $10 billion forex guess that “broke the Financial institution of England” in 1992. Since founding Duquesne Capital Administration in 1981, he is delivered annualized returns exceeding 30% earlier than closing to outdoors traders in 2010.
He now manages a household workplace that has continued beating the market with stellar numbers. If you wish to beat the market, researching Druckenmiller’s buys and maybe copying them may be a good way to beat the market, as that has traditionally paid off.
Druckenmiller’s largest holding is Natera. It’s a medical genetic testing firm that focuses on non-invasive, cell-free DNA (cfDNA) testing expertise. NTRA inventory has been one among Druckenmiller’s largest profitable strikes because it has gained over 500% since bottoming out in October 2023.
Druckenmiller constructed up his stake because the inventory traded sideways all through late 2022 to early 2023. As NTRA inventory lastly broke out and began rallying, Druckenmiller stored including to his stake.
He solely took income in Q1 2025 and once more in Q2 2025 earlier than shopping for the dip in Q3 2025.
The inventory has gained almost 70% since that dip and is continuous to rally increased.
Progress has been very sturdy. Income grew 34.66% year-over-year in Q3 2025 and beat analyst estimates. Natera remains to be loss-making, however analysts anticipate losses to slender. EPS is anticipated to show optimistic in 2028 with income persevering with to develop by double digits by means of the subsequent decade.
NTRA inventory constitutes 12.74% of Druckenmiller’s portfolio. His holdings listed here are value $517.4 million.
Insmed is a biopharma firm that largely focuses on pulmonary circumstances. The flagship product is ARIKAYCE, which is the primary and solely FDA-approved remedy for refractory Mycobacterium avium advanced (MAC).
